We narrowed to 2,781 results for: lox

#218877-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al eLife. 2026 Mar 18;14:RP108319. doi: 10.

Sept. 27, 2024

Academic Institutions and Nonprofits only

#137130-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-BFP (#137130). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-BFP plasmid DNA. EF1a-driven, Cre-dependent expression of BFP (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

March 19, 2021

Academic Institutions and Nonprofits only

#137163-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-ChR2-EYFP (#137163). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-ChR2-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of ChR2-EYFP for optogenetic activation (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#178329-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only

#104495-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE (#104495). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE plasmid DNA. CAG-driven, Cre-dependent GCaMP7s calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Oct. 3, 2019

Academic Institutions and Nonprofits only

#137156-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff 2.0-iC++-EYFP (#137156). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff 2.0-iC++-EYFP plasmid DNA. nEF-driven, Cre-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP (inhibited in presence of Flp) for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 25, 2020

Academic Institutions and Nonprofits only

#105715-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (#105715). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s plasmid DNA. EF1a-driven, Cre-dependent GCaMP6s fused to the presynaptic protein synaptophysin. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

Oct. 20, 2020

Academic Institutions and Nonprofits only

#137148-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP (#137148). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-Arch3.3-p2a-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of Arch3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#137155-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-iC++-EYFP (#137155). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-iC++-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of chloride-conducting channelrhodopsin iC++-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Dec. 1, 2020

Academic Institutions and Nonprofits only